MK-677 'not for me anymore': what the science says about quitting
Quick answer
MK-677 is an orally active ghrelin receptor agonist that stimulates growth hormone secretion and raises IGF-1, with two-year human trial data showing efficacy alongside consistent signals of increased fasting glucose and insulin resistance at standard doses. It is not FDA-approved and is frequently miscategorized as a peptide in wellness content, which obscures its distinct pharmacological profile. Discontinuation experiences vary based on individual metabolic baseline, duration of use, and whether bloodwork was monitored during the cycle.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team· This is not a transcript. It is our independent review of the video above.
What's this video probably claiming?
Based on the caption framing, creator @hackinggirly is likely describing a personal decision to stop using MK-677 (ibutamoren), a growth hormone secretagogue that has become one of the most discussed peptide-adjacent compounds on wellness TikTok. The 'not for me anymore' framing suggests she experienced side effects, hormonal changes, or lifestyle incompatibility that prompted her to discontinue. Common personal accounts in this space cite water retention, increased hunger, lethargy, or concerns about long-term insulin sensitivity. The 'everyone's wired differently' language is a popular way creators sidestep liability while still implying their experience is broadly instructive. It's not advice, technically. But 5,500 people just watched someone explain why they stopped taking a compound that affects growth hormone and IGF-1 levels, and most of them probably left with a strong impression either for or against it.
What does the science actually show?
MK-677 is not a peptide. It is an orally active ghrelin receptor agonist. That distinction matters because it is often grouped with injectable peptides like CJC-1295 or ipamorelin in wellness content, but it has a different mechanism, different risk profile, and more human trial data than most compounds discussed in this category. Nuttall et al. (1997, Journal of Clinical Endocrinology and Metabolism) showed MK-677 increased GH pulsatility and IGF-1 levels in healthy adults over two years at 25 mg/day without serious adverse events, but with notable increases in fasting glucose and insulin resistance. Murphy et al. (1998, same journal) found similar IGF-1 elevations in elderly subjects but flagged edema and muscle pain as common complaints. A 2008 study by Svensson et al. in the European Journal of Endocrinology confirmed IGF-1 increases but also found worsening glycemic markers in subjects predisposed to insulin resistance. The science is not overwhelmingly negative, but it is not clean either.
Where does the social media noise diverge from clinical reality?
The TikTok version of MK-677 is mostly sold as a sleep-enhancing, muscle-building, skin-improving shortcut that you just take orally, no injections required. That accessibility is exactly what makes it popular and exactly what makes the discourse irresponsible. What gets left out: the hunger increase (ghrelin agonism means you are pharmacologically hungrier, not just psychologically), the water retention that is often mistaken for fat gain in early weeks, and the real concern about prolonged IGF-1 elevation. Elevated IGF-1 is associated with proliferative risk in certain cancer-susceptible populations, per Renehan et al. (2004, Lancet), though causality in healthy adults remains unproven. Creators who say they stopped because it 'wasn't for them' are often describing real physiological signals. The problem is that without bloodwork and clinical oversight, they, and their viewers, have no idea what those signals actually mean.
What should you actually know?
If you are considering or currently using MK-677, the legitimate concerns are not abstract. Fasting insulin and fasting glucose should be monitored regularly because even sub-clinical insulin resistance compounds over time, especially if your diet is high in refined carbohydrates. IGF-1 levels should be tested at baseline and periodically during use. Edema and lethargy are common in the first four to eight weeks and do not always resolve. MK-677 is not FDA-approved for any indication. It is not a research chemical with no data, but it is also not a medication with a defined therapeutic window established for general wellness use. A creator stopping MK-677 because of personal experience is valid. But the takeaway for viewers should not be 'I should try it and see if it works for me.' It should be 'this compound has measurable endocrine effects, and I should understand those before I touch it.'
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Access rules depend on the compound and patient situation
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 9 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For MK-677 'not for me anymore': what the science says about quitting, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Ipamorelin, the first selective growth hormone secretagogue
Background source for ipamorelin selectivity and GH-secretagogue mechanism.
PubMed
The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation
Preclinical context that should not be overstated as consumer clinical evidence.
PubMed
GLP-1 receptor agonists versus metformin in PCOS: a systematic review and meta-analysis
Used for PCOS pages comparing metabolic and weight-management approaches.
PubMed
The efficacy and safety of GLP-1 agonists in PCOS women living with obesity
Supports PCOS, obesity, and hormonal-regulation context.
PubMed
Video claim decision path
Turn the claim into a safer next question
Direct answer
MK-677 'not for me anymore': what the science says about quitting should be treated as a claim to verify, then compared with evidence, safety context, and a provider review path.
Evidence check
Social clips are useful prompts, but they rarely show the full evidence base, contraindications, or dosing context.
Safety check
A viral claim can miss patient-specific risks, medication interactions, legal access, and source quality.
Next step
Use the health tools and supporting evidence to prepare questions for your clinician.
Helpful context before the funnel
Claim verdict
The useful answer behind this video
Claim being checked
MK-677 is an orally active ghrelin receptor agonist that stimulates growth hormone secretion and raises IGF-1, with two-year human trial data showing efficacy alongside consistent signals of increased fasting glucose and insulin resistance at standard doses.
FormBlends verdict
MK-677 is an orally active ghrelin receptor agonist that stimulates growth hormone secretion and raises IGF-1, with two-year human trial data showing efficacy alongside consistent signals of increased fasting glucose and insulin resistance at standard doses. It is not FDA-approved and is frequently miscategorized as a peptide in wellness content, which obscures its distinct pharmacological profile. Discontinuation experiences vary based on individual metabolic baseline, duration of use, and whether bloodwork was monitored during the cycle.
Patient-safe next step
Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- MK-677 is an orally active ghrelin receptor agonist that stimulates growth hormone secretion and raises IGF-1, with two-year human trial data showing efficacy alongside consistent signals of increased fasting glucose and insulin resistance at standard doses. It is not FDA-approved and is frequently miscategorized as a peptide in wellness content, which obscures its distinct pharmacological profile. Discontinuation experiences vary based on individual metabolic baseline, duration of use, and whether bloodwork was monitored during the cycle.
- MK-677 is not a peptide. It is an oral ghrelin receptor agonist with a distinct mechanism and risk profile from injectable peptides like ipamorelin or CJC-1295.
- Two-year human trial data (Nuttall et al., 1997) shows MK-677 at 25 mg/day reliably raises IGF-1 but also raises fasting glucose and worsens insulin sensitivity in a meaningful subset of users.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compound access, legal status, and product quality still need a separate safety check.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.
Start provider reviewWhat You'll Learn
- MK-677 is not a peptide. It is an oral ghrelin receptor agonist with a distinct mechanism and risk profile from injectable peptides like ipamorelin or CJC-1295.
- Two-year human trial data (Nuttall et al., 1997) shows MK-677 at 25 mg/day reliably raises IGF-1 but also raises fasting glucose and worsens insulin sensitivity in a meaningful subset of users.
- Common discontinuation complaints including water retention, increased hunger, and lethargy are physiologically real and tied to ghrelin agonism, not placebo or poor lifestyle choices.
- Prolonged IGF-1 elevation carries theoretical proliferative risk in cancer-susceptible individuals, per Renehan et al. (2004, Lancet), though causality in healthy adults using MK-677 has not been established.
- MK-677 is not FDA-approved for any use. It exists in a regulatory gray area that means no standardized dosing, no mandatory purity testing, and no formal post-market safety surveillance.
- Personal discontinuation stories on social media, even well-intentioned ones, cannot substitute for baseline and follow-up bloodwork including fasting insulin, fasting glucose, and IGF-1.
- 'Not for me' content influences viewer behavior regardless of disclaimers. If you are considering MK-677, that decision should start with a clinician who can order labs, not a TikTok comment section.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
Biohackinggirly🧪✨ · TikTok creator
5.5K views on this video
Replying to @Chrissy this one used to be my fave! Here’s what made me realize it’s not for me anymore. Everyone’s wired differently 🧠🫶🏼 *This is not advice and should not be perceived as such*
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by Biohackinggirly🧪✨, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.